Last reviewed · How we verify
NCT04932187
Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 3)
Phase 1 trial testing Capecitabine, Camrelizumab in Hepatobiliary, Pancreatic and Other Gastrointestinal Carcinoma (Non-stomach, Non-esophagi) in 20 participants. Status unknown.
1 July 2023
Quick facts
| Lead sponsor | Ruijin Hospital |
|---|---|
| Phase | Phase 1 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 20 |
| Start date | 1 August 2021 |
| Primary completion | 1 July 2023 |
| Estimated completion | 1 July 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- Capecitabine, Camrelizumab — full drug profile →
Conditions studied
- Hepatobiliary, Pancreatic and Other Gastrointestinal Carcinoma (Non-stomach, Non-esophagi) — all drugs for Hepatobiliary, Pancreatic and Other Gastrointestinal Carcinoma (Non-stomach, Non-esophagi) →
Sponsor
Ruijin Hospital
Who can join
18 and older, any sex, with Hepatobiliary, Pancreatic and Other Gastrointestinal Carcinoma (Non-stomach, Non-esophagi). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a single center phase 1 trial to observe safety and efficacy of metronomic capecitabine plus PD-L1 antibody camrelizumab to treat hepatobiliary, pancreatic and other gastrointestinal carcinoma (non-stomach, non-esophagi) patients who had disease progression after all standard regimens. This study is one of the cohorts of a multi-cohort trial called Combination of Metronomic capecitabine with Camrelizumab for treatment of refractory solid tumor (McCrest) trial.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
B7 Family Members in Pancreatic Ductal Adenocarcinoma: Attractive Targets for Cancer Immunotherapy.
Chen X, Li J, Chen Y, Que Z, et al · · 2022 · cited 3× · PMID 36499340 · DOI 10.3390/ijms232315005 -
Metastatic ovarian tumor from pancreatic cancer treated with combined immunotherapy: A case report.
Tao Y, Tang L, Zuo L, Ma Y, et al · · 2022 · cited 2× · PMID 36072000 · DOI 10.3892/ol.2022.13464 -
Lipid metabolism associated with efficacy of metronomic capecitabine and camrelizumab in gastrointestinal cancer: an exploratory clinical trial.
Zhou C, Yin Y, Shangguan C, Wu Q, et al · · 2025 · cited 1× · PMID 41121239 · DOI 10.1186/s12916-025-04377-4
Verify or expand the search:
- PubMed search for NCT04932187
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Capecitabine, Camrelizumab
Trials testing the same drug.
- NCT04510818 — Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 2) · Phase 1 · unknown
Other Ruijin Hospital trials
Trials by the same sponsor.
- NCT07589361 — Safety and Efficacy of Vertebral Body-Sparing Craniospinal Irradiation With Proton Therapy in Pediatric Tumors · not yet recruiting
- NCT07449507 — Partially Hydrolyzed Whey Protein Formula for Infants With Mild Allergy · NA · not yet recruiting
- NCT07496385 — Clinical Study on the Efficacy of Subglottic Suction in Mechanically Ventilated Patients Guided by Bedside Ultrasound · NA · not yet recruiting
- NCT07511114 — A Study Comparing C Pola R-CHP+X With CR-CHOP in the Treatment of Previously Untreated DEL Under the Guidance of Genotyp · Phase 3 · not yet recruiting
- NCT07514169 — The Efficacy and Safety of Pola-ZR-Glo in Older Treatment-naive Patients With LBCL · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04932187 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ruijin Hospital
- Last refreshed: 17 September 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04932187.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing